Clinical bottom line
Selective phosphoinositide 3-kinase (PI3K) inhibitors represent a promising therapeutic class for patients with relapsed or refractory follicular lymphoma (FL), offering targeted inhibition of key signaling pathways involved in lymphoma cell survival and proliferation. Recent clinical evidence suggests that newer agents with improved isoform selectivity and safety profiles may enhance efficacy while mitigating toxicities traditionally associated with PI3K inhibition. However, optimal sequencing, combination strategies, and long-term safety remain areas requiring further investigation. These agents provide an important addition to the expanding armamentarium for relapsed/refractory FL, particularly for patients who have exhausted standard chemoimmunotherapy options.
What the evidence shows
The PI3K pathway is a critical driver of B-cell receptor signaling and tumor cell survival in FL, making it a rational target for therapy. Several selective PI3K inhibitors have been evaluated in relapsed/refractory FL, with recent data highlighting agents such as copanlisib, linperlisib, and duvelisib.
Copanlisib, a predominantly PI3K-α and -δ inhibitor administered intravenously, demonstrated efficacy in relapsed/refractory FL including grade 3b cases, with manageable toxicity when combined with chemotherapy (Case Medical Research, 2019). Oral agents such as linperlisib and duvelisib, both targeting PI3K-δ with varying degrees of isoform selectivity, have been compared in cost-effectiveness analyses and clinical trials, showing comparable efficacy but differing safety and tolerability profiles (Bai et al., 2026). Linperlisib, in particular, has been noted for a favorable balance of efficacy and adverse events in Chinese patient populations.
A comprehensive review of relapsed/refractory FL management underscores the evolving role of PI3K inhibitors as monotherapy or in combination regimens, especially after failure of anti-CD20 antibodies and chemotherapy (Bartlett et al., 2025; Skarbnik et al., 2023). Treatment selection increasingly incorporates patient-specific factors, including prior therapies, comorbidities, and risk of immune-mediated toxicities.
Emerging agents such as IBI376, evaluated in early-phase studies, aim to refine targeting and improve tolerability, though data remain preliminary (Case Medical Research, 2020). Overall, PI3K inhibitors provide an important option for patients with limited alternatives, with demonstrated response rates and progression-free survival benefits in relapsed/refractory FL cohorts.
Caveats and uncertainty
Despite encouraging efficacy, PI3K inhibitors have been associated with immune-related adverse events including colitis, pneumonitis, and infections, necessitating careful patient monitoring and management. The risk-benefit ratio varies by agent and patient population, and long-term safety data are limited. Differences in isoform selectivity and dosing schedules impact toxicity profiles but complicate direct comparisons.
Cost-effectiveness analyses, such as the comparison between linperlisib and duvelisib in China, highlight economic considerations that may influence access and treatment decisions but may not generalize globally (Bai et al., 2026). Additionally, most data derive from single-arm or phase II trials; randomized controlled trials comparing PI3K inhibitors head-to-head or against other novel agents are sparse.
The optimal sequencing of PI3K inhibitors relative to other targeted therapies, including bispecific antibodies and CAR T-cell therapies, remains undefined. Resistance mechanisms and biomarkers predictive of response are under active investigation but not yet clinically validated.
How this may change practice
Selective PI3K inhibitors are likely to become integral components of relapsed/refractory FL treatment algorithms, particularly for patients ineligible for or refractory to chemoimmunotherapy. Their use requires balancing efficacy with immune-mediated toxicity risks, emphasizing the need for vigilant adverse event monitoring and patient education.
Clinicians should consider individual patient factors, prior treatment history, and local drug availability when selecting among PI3K inhibitors. Emerging data may support combination regimens incorporating PI3K inhibitors with other targeted agents or immunotherapies, potentially enhancing outcomes.
Cost considerations and healthcare system factors will influence adoption, underscoring the importance of pharmacoeconomic data in guiding therapy choice. Ongoing trials and real-world evidence will clarify long-term safety, optimal sequencing, and patient selection criteria, enabling more personalized approaches.